Individualization Treatment Through a Self-managed Web-based Solution in Ulcerative Colitis

NCT ID: NCT03604536

Last Updated: 2022-03-09

Basic Information

• Recruitment Status: TERMINATED
• Total Enrollment: 1 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-12-02
• Study Completion Date: 2021-12-31

Brief Summary

This study investigates the effect of individualized monotherapy with Mesalazine (Pentasa Sachet ®) on time to remission in patients with mild to moderate UC in an eHealth setting.

Detailed Description

More than 3 million Europeans suffer from inflammatory bowel disease (IBD), where Crohn's Disease (CD) and Ulcerative Colitis (UC) are the most common forms. They are chronic, relapsing and remitting diseases resulting in uncontrolled inflammation of the gastrointestinal (GI) tract with symptoms of diarrhoea, abdominal pain, weight loss and blood in the stools. The treatment aims to relieve and prevent GI tract inflammation and consists of anti-inflammatory and immunosuppressive drugs or surgical removal of the colon as a final option. The main treatment option for mild to moderate UC is Aminosalicylate. Mesalazine (5-aminosalicylic acid), both orally and topically, has been proven to be an effective treatment option for inducing as well as maintaining remission in patients with UC.

Pentasa Sachet are Mesalazine micro granules coated in ethyl cellulose with high (95%) 5-aminosalicylic acid (5-ASA) load. The coating provides a prolonged release of Mesalazine, allowing a continuous action from small bowel to rectum. Approximately 75% of the micro granules are released in the colon. This reduces the number of applications needed per day and is therefore considered to be a more desirable option by the patients. Once daily administrated 5-aminosalicylic acid (5-ASA) has been shown to be as effective as conventional dosing.

Fecal Calprotectin (FC) is an accurate biomarker of GI tract inflammation. FC correlates well with endoscopic disease activity and consequently serves as a substitute marker for mucosal healing as well as a clinical tool for disease monitoring. A home testing kit with a smart phone application, which only takes 18 min to carry out, has been developed. Thereby, facilitating the opportunity of telemonitoring of the disease course and stimulating patient engagement, empowerment and adherence to treatment.

Medication adherence is essential for maintaining remission, since non-adherence is one of the main causes of disease activity. A combined therapy of oral and topical 5-ASA is recommended by current guidelines for the treatment of active mild to moderate UC. However, patient adherence to oral 5-ASA is poor (approximately 60%), and even poorer to topical therapy (approximately 32%). A previous eHealth trial on individualized oral 5-ASA therapy reported higher adherence rates than previous studies on standard care. In addition, 90% of the study patients responded with remission on monotherapy and only 10% needed a combined therapy with topical treatment.

Web-based treating solutions (eHealth) have shown to optimize treatment effect in chronic diseases such as asthma, type 1 diabetes, and coagulation diseases. A web-based treatment solution for IBD patients, Constant-care, was in 1997 launched by Dr. Pia Munkholm. The web-program has since been proven to be an effective clinical tool, resulting in enhanced compliance, empowerment, improved quality of life and decreased relapse duration in IBD patients. Constant-Care consists of an education package and a disease-monitoring package. The disease monitoring part of the program is built upon an algorithm of two variables; FC and a validated disease activity questionnaire, Simple Clinical Colitis Activity Index (SCCAI) for UC patients. The FC values are acquired by the patients through a home testing kit and the disease activity questionnaire is filled out by the patients in the web- program. The eHealth system cumulates the data immediately, and subsequently presenting the result, a Total inflammatory Burden Score (TIBS), to the patients as a visual "traffic light" indicator of disease activity. Patients receive treatment advices by the program depending on the severity of the disease: green- remission, yellow- moderate activity, red-severe activity.

The disease monitoring part also consists of Patient-Related Outcome (PRO) questionnaires regarding quality of life, disability, fatigue, disease course type and compliance. The International Organization for the study of Inflammatory Bowel Disease (IOIBD) has since 2015 recommended the use of PRO's as a fundamental part of measuring treatment outcome in both UC and CD.

The primary aim of the study is to investigate the effect of individualized monotherapy with Mesalazine (Pentasa Sachet ®) on time to remission (clinical and Paraclinical (green TIBS)) in patients with mild to moderate UC in an eHealth setting. The investigators hypothesize that the web based therapy program will reduce the time to remission compared to standard care.

Conditions

Inflammatory Bowel Diseases; Ulcerative Colitis

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• Fulfil the Copenhagen Diagnostic criteria for UC
• Age between 18 and 75 years
• New and relapse patients diagnosed with Mild-to-moderate UC
• Current relapse (minimum 1 out of 2) SCCAI>2 (with a positive score in the variable of blood in stool) FC ≥200
• Diagnosed with left sided or extensive UC(24)
• Understand written and spoken Danish
• Easy access to internet and smartphone

Exclusion Criteria

• Evidence of enteric infection
• Treatment with immunomodulators such as steroids, azathioprine, methotrexate, or infliximab within the last 8 weeks
• Two or more courses of oral steroids in the past 12 months
• Diagnosed with proctitis
• Severe disease activity (SCCAI >6 or FC ≥600)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ferring Pharmaceuticals

INDUSTRY

Sponsor Role: collaborator

Nordsjaellands Hospital

OTHER

Sponsor Role: lead

Responsible Party

Petra Weimers

Prinicipal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Pia Munkholm, Prof

Role: STUDY_DIRECTOR

North Zealand University Hospital

Locations

North zealand university hospital

Frederikssund, , Denmark

Countries

Denmark

References

Vinding KK, Elsberg H, Thorkilgaard T, Belard E, Pedersen N, Elkjaer M, Marker D, Carlsen K, Burisch J, Munkholm P. Fecal Calprotectin Measured By Patients at Home Using Smartphones--A New Clinical Tool in Monitoring Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 Feb;22(2):336-44. doi: 10.1097/MIB.0000000000000619.

Reference Type: BACKGROUND

PMID: 26535869 (View on PubMed)

Pedersen N, Thielsen P, Martinsen L, Bennedsen M, Haaber A, Langholz E, Vegh Z, Duricova D, Jess T, Bell S, Burisch J, Munkholm P. eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2014 Dec;20(12):2276-85. doi: 10.1097/MIB.0000000000000199.

Reference Type: BACKGROUND

PMID: 25248002 (View on PubMed)

Elkjaer M, Shuhaibar M, Burisch J, Bailey Y, Scherfig H, Laugesen B, Avnstrom S, Langholz E, O'Morain C, Lynge E, Munkholm P. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut. 2010 Dec;59(12):1652-61. doi: 10.1136/gut.2010.220160.

Reference Type: BACKGROUND

PMID: 21071584 (View on PubMed)

Pedersen N, Elkjaer M, Duricova D, Burisch J, Dobrzanski C, Andersen NN, Jess T, Bendtsen F, Langholz E, Leotta S, Knudsen T, Thorsgaard N, Munkholm P. eHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn's disease. Aliment Pharmacol Ther. 2012 Nov;36(9):840-9. doi: 10.1111/apt.12043.

Reference Type: BACKGROUND

PMID: 22971016 (View on PubMed)

Other Identifiers

H-17038710

Identifier Type: -

Identifier Source: org_study_id